Live Feeds
● LIVE Updated 1h ago · 17 sources tracked

Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

Moderna and Merck announced that their personalized mRNA cancer vaccine, when combined with the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with standard treatment. The findings come from the randomized phase 3 INTerpath-001 trial, which evaluated patients with completely resected high-risk melanoma after surgery. The combination also reduced the risk of distant metastasis or death by 38%, according to data presented at the ESMO Congress 2026. While some oncologists are hailing the vaccine as a major breakthrough, overall survival data remain immature.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (17)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna and Merck's personalized mRNA vaccine reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
  • ✓ A personalized mRNA vaccine plus Keytruda cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial.
  • ✓ Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.
  • ✓ The combination also reduced risk for distant metastasis or death by 38%, findings scheduled for presentation during ESMO Congress showed.
🛡️ Source Corroboration: 17 independent reporting domains (100% confidence) ⏱ Read time: ~3 min

What changed

Moderna and Merck released top-line phase 3 trial results at the ESMO Congress 2026 showing a 42% reduction in melanoma recurrence or death.

Live updates

  1. Personalized mRNA Vaccine Cuts Melanoma Return Risk in Phase 3 Trial

    Moderna and Merck announced that their personalized mRNA cancer vaccine, when combined with the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with standard treatment. The findings come from the randomized phase 3 INTerpath-001 trial, which evaluated patients with completely resected high-risk melanoma after surgery. The combination also reduced the risk of distant metastasis or death by 38%, according to data presented at the ESMO Congress 2026. While some oncologists are hailing the vaccine as a major breakthrough, overall survival data remain immature.

    Why it matters

    The late-stage trial results mark a significant step forward in the clinical development of individualized mRNA therapeutics for solid tumors. The treatment approach pairs surgery and standard adjuvant immunotherapy with a custom mRNA vaccine designed specifically for each patient's tumor profile. Despite the positive clinical efficacy data on recurrence, financial markets have reacted with volatility, and Moderna stock extended losses as investors digested the trial results.

    What is confirmed

    • Moderna and Merck's personalized mRNA vaccine reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
    • A personalized mRNA vaccine plus Keytruda cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial.
    • Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.
    • The combination also reduced risk for distant metastasis or death by 38%, findings scheduled for presentation during ESMO Congress showed.
    • Overall survival data are not yet mature.

    What to watch next

    • Maturation of overall survival data from the INTerpath-001 trial
    • Further clinical developments regarding personalized mRNA vaccines for cancer
    Sources used for this update (14)
    1. help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    2. arstechnica.com — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    3. The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
    4. NBC News — Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
    5. Yahoo Finance — Moderna stock extends losses as investors digest melanoma vaccine trial data
    6. WSJ — Moderna Investors Should Brace for More Whiplash
    7. WIRED — New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
    8. www.nbcnews.com — Personalized mRNA vaccine for melanoma cut risk of cancer’s ...
    9. www.medicaldaily.com — Personalized mRNA Melanoma Vaccine Cut Recurrence or Death Risk 42% in Phase 3 Trial, but Survival Data Pending - Medical Daily
    10. www.newsbreak.com — Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial - NewsBreak
    11. 13wham.com — Moderna-Merck personalized mRNA melanoma vaccine cuts relapse risk in late-stage trial
    12. www.news-medical.net — Personalized mRNA cancer vaccine cuts melanoma recurrence ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community